AUTHORS
Ramza Ishac, MD, Hagop Kantarjian, MD2, Ghayas C. Issa, MD3, Michelle Nwachukwu, DO4, Naveen Pemmaraju, MD5, Gautam Borthakur, MD6, Abhishek Maiti, MBBS7, Courtney DiNardo, MD, MSCE8, Guillermo Garcia-Manero, MD9, Maro Ohanian, DO10, Elias Jabbour, MD11, Fadi G. Haddad, MD12
AFFILIATIONS
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
ABSTRACT
Background: The management of chronic myeloid leukemia (CML) in pregnancy remains challenging due to the risk of teratogenicity associated with the use of tyrosine kinase inhibitors, particularly when administered during the first trimester. This study aims to characterize maternal and fetal outcomes and evaluate the risk of congenital malformations among patients with CML exposed to hydroxyurea during pregnancy.
Methods: We conducted a retrospective analysis of all pregnant patients with a diagnosis of CML treated to our institution and who received hydroxyurea at any point during pregnancy. We analyzed the outcomes of the pregnancy, the fetal outcomes, the presence or absence of congenital malformations and low birth weight and evaluated the outcomes of the patients following delivery.
Results: A total of 20 pregnancies from 19 women with CML were included (one patient had two separate pregnancies). All pregnancies occurred in women with chronic-phase CML. The median maternal age at the beginning of the pregnancy was 29 years (range, 18-40) and the median age at the diagnosis of CML was 27 years (range, 17-40). Hydroxyurea exposure occurred during the first trimester only in one pregnancy, during the second trimester only in one, during the third trimester only in six, during the second and third trimesters in seven, and throughout all three trimesters in five pregnancies. The median duration of hydroxyurea exposure was 144 days (range, 3-217) and the median dose of hydroxyurea given was 2 grams/day (range, 0.5-6).
Among the 20 pregnancies, 18 (90%) resulted in live birth including twins in one pregnancy, and two (10%) ended in miscarriage. The median gestational age at the time of delivery was 37 weeks (range, 33 weeks 2 days to 40 weeks 2 days). Six pregnancies (35%) resulted in preterm birth (defined as <37 weeks’ gestation). The median birth weight was 3,011 g (range, 2,410-3,390), and one pregnancy (5%) resulted in a low-birth weight infant (defined as <2,500g). No congenital anomalies or structural malformations were recorded among the 19 live-born neonates.
Disease progression to accelerated- or blast-phase CML was documented in four pregnancies, three of which were off TKI. One patient progressed one month after a miscarriage while three patients progressed within the three years following deliveryBest overall response following delivery was available for 16 pregnancies. Complete molecular response was achieved in seven pregnancies (44%), MR4 in six (38%), major molecular response in one (6%), and complete cytogenetic response in two (13%).
Conclusion: Among women with CML, the exposure to hydroxyurea during pregnancy was associated with relatively favorable maternal and pregnancy outcomes. No congenital anomalies or malformations were reported among all 19 live-born neonates. These findings expand the limited evidence regarding the use of hydroxyurea in pregnancy, particularly among patients with CML.
DISCLOSURES
Ramza Ishac, MD: No relevant conflicts of interest to declare.